Biomerica Inc(BMRA) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 39 full-time employees. The firm's medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians' offices and over-the-counter drugstores). The firm operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The firm's diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations. The firm primarily focuses on products for gastrointestinal (GI), food intolerances, diabetes and esoteric tests. The firm's diagnostic products use immunoassay technology.

Current Price

$4.40

RSI

37.193

Beta:

-0.706563

January 14, 2021
223.9K
-2.9M

-8.546 %
29.337 %
-203.295 %
-40.931 %

$6,692,711
$5,200,682
$5,564,185
$5,791,670
$5,139,820
$4,962,373
28.689 %
-6.990 %
-4.088 %
12.682 %
3.576 %

$-2,331,664
$-2,368,823
$-1,434,028
$-908,561
$-795,990
$-646,434
1.594 %
-39.462 %
-36.643 %
-12.390 %
-18.789 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.